martes, 18 de diciembre de 2018

Valproate use in migraine prevention in women of childbearing age – Why are we still discussing it? - On Health

Valproate use in migraine prevention in women of childbearing age – Why are we still discussing it? - On Health

Dr Anna Andreou

Dr Andreou is an academic at King’s College London and the director of headache research at the Headache Centre, Guy’s and Se Thomas’ NHS Trust and King’s College London in UK. She serves on the advisory board of The Journal of Headache and Pain. 

Twitter profile: @ap_andreou


Valproate use in migraine prevention in women of childbearing age – Why are we still discussing it?

The European Headache Federation (EHF) and European Medicines Agency (EMA) have published their latest clinical recommendation on valproate use for migraine prophylaxis in women of childbearing age in The Journal of Headache and Pain. We have invited Dr Anna Andreou, director of headache research at the Headache Centre, King’s College London and The Journal of Headache and Pain’s advisory board member to explain the challenges in preventive treatment of migraine, and why valproate should be used with caution in women of childbearing age.

What preventive treatment options are there for migraine?

No hay comentarios:

Publicar un comentario